ArticleBMC cancer2022

Inhibition of hyperprogressive cancer disease induced by immune-checkpoint blockade upon co-treatment with meta-tyrosine and p38 pathway inhibitor.

Daniela R Montagna et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.